Vaxart receives stop work order from BARDA on Phase 2b oral COVID-19 vaccine trial

Vaxart, Inc.

ATI/BARDA directed Vaxart to stop all work on Project Agreement RRPV-24-04-NGVx-003 for oral COVID-19 vaccine.
Company may only continue follow-up for already dosed participants in the 10,000-person cohort; enrollment about half complete.
No reason provided; DSMB had determined on July 14 that the study could proceed without modification.
Company expects a follow-up notice with further details; no additional funding or termination decision announced.

item 1.01item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.